Responses
Regular and Young Investigator Award Abstracts
Clinical Trial Completed
616 Pharmacokinetics and safety of a subcutaneous formulation of nivolumab (NIVO SC) monotherapy: updated results from the phase 1/2 CheckMate 8KX study
Compose a Response to This Article
Other responses
No responses have been published for this article.